Poulin, R., Baker, D., Poirier, D., et al. Multiple actions of synthetic ''progestins" on the growth of ZR-75–1 human breast cancer cells: An in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids. Breast Cancer Research and Treatment 17:197, 1990.
Pronzato, P., Brema, F., Amoroso, D., et al. Megestrol acetate: Phase II study of a single daily administration in advanced breast cancer. Breast Cancer Research and Treatment 17:51–55, 1990.
Purohit, A., Lai, L.C., Singh, A., et al. The effect of medroxyprogesterone acetate on aromatase and DNA polymerase activities in breast tumours. Journal of Steroid Biochemistry 34:443, 1989.
Reddel, R.R., Alexander, I.E., Koga, M., et al. Genetic instability and the development of steroid hormone insensitivity in cultured T47D human breast cancer cells. Cancer Research 48:4340, 1988.
Robinson, S.P., and Jordan, V.C. Reversal of the antitumor effects of tamoxifen by progesterone in the 7, 12-dimethylbenzanthracene-induced rat mammary carcinoma model. Cancer Research 47:5386, 1987.
Rochefort, H., and Chalbos, D. RU 486: A full progestin antagonist in human breast cancer cell lines. P. 307 in The Antiprogestin Steroid RU 486 and Human Fertility Control. Baulieu, E.E., and Segal S.J., eds. New York: Plenum Publishing Corporation, 1985.
Russo, I.H., Gimotty, P., Dupuis, M., et al. Effect of medroxyprogesterone acetate on the response of the rat mammary gland to carcinogenesis. British Journal of Cancer 59:210, 1989.
Sartorius, C.A., Tund, L., Takimoto, G.S., et al. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. Journal of Biological Chemistry 268:9262–9266, 1993.
Sarup, J.C., Rao, K.V.S., Fox, C.F. Decreased progesterone binding and attenuated progesterone action in cultured human breast carcinoma cells treated with epidermal growth factor. Cancer Research 48:5071, 1988.
Schlesselman, J.J. Oral contraceptives and breast cancer. American Journal of Obstetrics and Gynecology 163(2):1379–1387, 1990.
Schneider, M.R., Michna, H., Nishino, Y., et al. Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat. European Journal of Cancer and Clinical Oncology 25:691–701, 1989.
Sedlacek, S.M., and Horwitz, K.B. The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids 44:467, 1984.
Sheridan, P.L., Krett, N.L., Gordon, J.A., et al. Human progesterone receptor transformation and nuclear down-regulation are independent of phosphorylation. Molecular Endocrinology 2:1329–1342, 1988.
Sutherland, R.L., Hall, R.E., Pang, G.Y.N., et al. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Research 48:5084, 1988.
Tora, L., Gronemeyer, H., Turcotte, B., et al. The N-terminal region of the chicken progesterone receptor specifies target gene activation. Nature 333:185, 1988.
Vegeto, E., Allan, G.F., Schrader, W.T., et al. The mechanisms of RU 486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69:703, 1992.
Vignon, F., Bardon, S., Chalbos, D., et al. Antiestrogenic effect of R 5020, a synthetic progestin in human breast cancer cells in culture. Journal of Clinical Endocrinology and Metabolism 56:1124, 1983.
Welsch, C.W. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: A review and tribute to Charles Brenton Huggins. Cancer Research 45:3415, 1985.